- Identify biomarkers for PD diagnosis, early detection, patient stratification, disease progression, prognosis or response to treatment. This is the objective of the VHIP Project that the team is carrying out.
- Identify new molecular targets for potential therapeutic intervention and prevention.
- Develop novel therapeutic strategies with disease-modifying potential.
- Unravel molecular pathways common to other neurodegenerative diseases and, in a broader sense, brain aging.
eCORE
- Advanced Therapies and Advanced Interventions, Nanomedicine, Transplant & Donation
- Brain & Mind and Behaviour
- Chronic, Prevalent Diseases & Aging
Team
Group Leader
Miquel Vila Bover
Principal Investigator (PI)
Marta Martínez Vicente, Jordi Bové Badell, Jorge Hernández Vara, Ariadna Laguna Tuset, Oriol de Fabregues-Boixar Nebot
Researchers
Daniela Samaniego Toro, David Ramos Vicente, Javier Hoyo Pérez, Núria Peñuelas Peñarroya, Marta González Sepúlveda, Thais Cuadros Arasa, Mercedes Arrué Gonzalo
PhD Students
Silvia Enríquez Calzada, Tsakogias Iraklis, Alba Nicolau Vera, Anna Garcia Serra, Camille Guillard Sirieix, Eddie Pradas Gracia, Gerard Roch Alba, Joana Margalida Cladera Sastre, Maria Camprodon Gomez, Marina Lorente Picón, Marta Montpeyó Garcia-Moreno
Lab Technicians
Annabelle Parent, Jordi Riera Heredia, Maria Belen Garcé Rivarola, Pablo Castillo Sánchez, Maria Sellés Altés
Selected Publications
Authors: Laguna A, Peñuelas N, Gonzalez-Sepulveda M, Nicolau A, Arthaud S, Guillard-Sirieix C, Lorente-Picón M, Compte J, Miquel-Rio L, Xicoy H, Liu J, Parent A, Cuadros T, Romero-Giménez J, Pujol G, Giménez-Llort L, Fort P, Bortolozzi A, Carballo-Carbajal I, Vila M.
Modelling human brain-wide pigmentation in rodents recapitulates age-related multisystem neurodegenerative deficits
Nature Communications (2024) 15(1):8819
DOI: 10.1038/s41467-024-53168-7
IF: 14.7
Outeiro TF, Kalia LV, Bezard E, Ferrario J, Lin CH, Salama M, Standaert DG, Taiwo L, Takahashi R, Vila M, Mollenhauer B, Svenningsson P
Basic Science in Movement Disorders: Fueling the Engine of Translation into Clinical Practice
Movement Disorders (2024) 39(6):929-933
DOI: 10.1002/mds.29802
IF: 8.6
Stefanie Lerche, Isabel Wurster, Enza Maria Valente, Micol Avenali, Daniela Samaniego, Ariadna Laguna, Marta Martínez-Vicente, Jorge Hernández-Vara, Andrea Sturchio, Per Svenningsson, Sethu Sankaranarayanan, Kathrin Brockmann
CSF Sphingolipids in Parkinson Disease and Dementia with Lewy Bodies with and without GBA1 variants
npj Parkinson’s Disease, 2024, 10 (1), 198
DOI: 10.1038/s41531-024-00820-0
IF: 6.7
Montpeyo M, Pérez-Carmona N, Cubero E, Delgado A, Ruano A, Carrillo J, Bellotto M, Martinez-Vicente; Garcia-Collazo AM
Developing Allosteric Chaperones for GBA1-Associated Disorders-An Integrated Computational and Experimental Approach
Int J Mol Sci.Dec 24;26(1):9., 2024
DOI: 10.3390/ijms26010009
IF: 5.6
Laura Castillo-Ribelles; Jose Antonio Arranz-Amo; Jorge Hernández-Vara; Daniela Samaniego-Toro; Silvia Enriquez-Calzada; Sara Lucas-Del Pozo; Maria Camprodon-Gomez; Ariadna Laguna; Mercedes Arrúe Gonzalo; Roser Ferrer; Marta Martinez-Vicente; Marta Martinez-Vicente
Evaluation of a Liquid Chromatography-Tandem Mass Spectrometry Method for the Analysis of Glucosylceramide and Galactosylceramide Isoforms in Cerebrospinal Fluid of Parkinson's Disease Patients
Analytical Chemistry. Aug 6;96(31), pp. 12882 - 12882. 2024
DOI: 10.1021/acs.analchem.4c02654
IF: 7.4
Selected Projects
Activity and connectivity drive neuronal vulnerability and disease progression in Parkinson’s disease
Principal Investigator: Miquel Vila
Agency: Aligning Science Across Parkinson’s (ASAP, USA)
Funding: 1,485,066 €
Period: 2021-2025
Targeting neuromelanin-linked neuronal dysfunction and degeneration in ageing and Parkinson’s disease using a combined imaging and brain stimulation approach
Principal Investigator: Miquel Vila
Agency: EU Joint Programme Neurodegenerative Disease Research (JPND)
Funding: 249,986 €
Period: 2021-2024
New nanotechnological therapy for Parkinson´s disease: nose to brain delivery of GBA-polymer nanoconjugates
Principal Investigator: Marta Martínez-Vicente
Agency: Obra Social Fundación la Caixa
Funding: 599,723 €
Period: 2022-2025
NanoERT: nano-delivery platform for Enzyme Replacement Therapy in Parkinson's and Gaucher's disease
Principal Investigator: Marta Martínez-Vicente
Agency: AGAUR
Funding: 154,000 €
Period: 2024-2026
The Gut-Brain axis in Parkinson's disease for biomarkers and therapeutic development
Principal Investigator: Ariadna Laguna
Agency: Ministerio de Ciencia e Innovación del Gobierno de España
Funding: 200,000 €
Period: 2024-2026
Patents
Glucocerebrosidase (GBA) polymer conjugate, preparation method and use for nanotechnological based Enzyme Replacement Therapy
Priority Number: PCT/EP2023/083626
Priority Date: February 2024
Applicants: VHIR-UAB
Selected Dissemination Activities
Cajal Month
Place: Catalan Society of Biology
Date: 01/11/2024
Brief: Month full of dissemination activities around the life and legate of Dr. Santiago Ramón y Cajal
MORE INFO
III Jornada de Parkinson Vall d’Hebron
Place: Barcelona
Date: 06/06/2025
Brief: People living with Parkinson and their caregivers
MORE INFO
International Day of Women and Girls in Science
Place: Vall d’Hebron Research Institute
Date: 02/11/2024
Brief: Science workshop for primary school students at VHIR
Dia Mundial del Parkinson 2024
Place: Hospital de Santa Creu i Sant Pau
Date: 04/08/2024
Brief: El comitè mèdic Respon als ciutadans
International Science Day in Schools
Place: Vilafranca del Penedès
Date: 01/01/1970
Brief: Science workshop for high-school students
